Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Mar 27, 2022; 14(3): 525-534
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.525

Table 4 Chemotherapy drug classes employed

Chemotherapy drug classes	Examples
Platinum-containing agents	(Cisplatin, carboplatin, oxaliplatin)
Folate antagonists	(Methotrexate, pemetrexed)
Pyrimidine compounds	(Fluorouracil, capecitabine, cytarabine, gemcitabine, decitabine)
Purine analogues	(Mercaptopurine, fludarabine, cladribine, clofarabine)
Alkylating agents	(Cyclophosphamide, ifosfamide, melphalan, bendamustine, busulfan)
Anthracyclines	(Daunorubicin, doxorubicin, epirubicin, idarubicin, bleomycin)
Topoisomerases	(Topotecan, etoposide, irinotecan)
Cytidine analogues	(Azacytidine, decitabine)
Immunosuppressants	(Tacrolimus, cyclosporine)
Immunomodulatory drugs	(Ienalidomide, thalidomide)
Mitotic inhibitors	(Paclitaxel, docetaxel, vinblastine, vincristine)
Hormonal therapies	(Tamoxifen)
Targeted therapies other than rituximab	(e.g., cetuximab, bortezomib, alemtuzumab)

Citation: Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534
URL: https://www.wjgnet.com/1948-5182/full/v14/i3/525.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i3.525

Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534 [PMID: 35582286 DOI: 10.4254/wjh.v14.i3.525]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.